No Data
No Data
Earnings Preview: SLNO to Report Financial Results Post-market on May 07
LogiCare3PL Supports Commercial Launch of Soleno Therapeutics' VYKAT XR Following FDA Approval
Piper Sandler Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $145
Soleno Therapeutics Price Target Raised to $145.00/Share From $93.00 by Piper Sandler
Soleno Therapeutics Is Maintained at Overweight by Piper Sandler
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET